Program
MET233
A development code. Also written as “MET233 and MET097”.
Its studies are mostly in Obesity, led by Pfizer.
Furthest: phase 2, since Apr 3, 20252 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 2since Apr 3, 2025 | Apr 3, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2025First study: phase 2 study in ObesityFirst studyNCT06924320 · 201 enrolled · United States
- Jun 6, 2025Phase 1 study in ObesityNCT07022977 · 145 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07022977Obesity · United States | 1 | Completed | May 28, 2026 | 145 |
| NCT06924320Obesity · United States | 2 | Completed | Sep 29, 2026 | 201 |
How it is read
Names in the registry
- “MET233”, 1 entry
- “MET233 and MET097”, 1 entry
Codes read as this program: MET233.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.